SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

The year in cardiovascular medicine 2021: dyslipidaemia

█ Current opinion

Lale Tokgozoglu1, Carl Orringer2, Henry N. Ginsberg3, and Alberico L. Catapano4
1Department of Cardiology Hacettepe University Faculty of Medicine, Sıhhiye, 06100 Ankara, Turkey;
2Department of Preventive Cardiovascular Medicine, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL, USA;
3Department of Medicine, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA;
4Department of Pharmacological and Biomolecular
Sciences, University of Milan and IRCCS Multimedica, Milano, Italy


The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.


click here to read the full article

click here to read the pdf